Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted.